Log In | Shopping Cart | Advanced Search

Anti-IL-13RA2 monoclonal antibody, recombinant

Catalog #: EG-373

$250.00

Qty:

EG-373 Anti-IL13Ra2-M2

Product Name	Anti-IL-13RA2 monoclonal antibody, recombinant
Cat #	EG-373
Size	100 µg
Key features	Rabbit monoclonal antibody produced in 293 cells with serum-free, protein-free medium, purified with protein A column; High batch-to-batch consistency and reproducibility; Long term security of supply;
Clone number	M2
Immunogen	Recombinant extracellular domain of interleukin 13 receptor alpha 2 (IL-13RA2) that was expressed and purified from 293 cells
Reaction target	Extracellular region of IL-13RA2
Species Cross-Reactivity	Human
Applications	Flow Cytometry; IP; ELISA;
Working concentrations	Flow cytometry and ELISA: 5 µg/ml of final concentration is suggested. IP: 10 μg in 0.3-0.5 mg cell lysates is suggested.
Background	The interleukin-13 receptor alpha 2 (IL-13RA2) is a high-affinity membrane receptor for interleukin-13 (IL-13). IL-13 is a T helper 2（Th2）cell-derived pleiotropic immune regulatory cytokine that binds available IL-13RA2 with 50-fold higher affinity than the ubiquitously expressed receptor named interleukin-13 receptor alpha 1 (IL-13RA1) [1]. Under normal physiological conditions, IL-13 binds to the low-affinity receptor IL-13RA1 monomer and further forms a heterodimeric complex with IL-4RA, which subsequently triggers Janus kinase and signal transducer activation and activator of transcription (STAT). However, in cancer cells, IL-13 can bind IL-13Rα2 with high affinity in an IL-4-independent manner. IL-13RA2 is over-expressed in a vast majority of human patients with high-grade astrocytomas like glioblastoma, but not in normal brain tissues. Therefore, IL-13RA2 is a potential target for immunotherapy of glioblastoma, which is one of the most lethal brain tumors and there are no curative treatment modalities for this type of cancer. IL-13 fused pseudomonas exotoxin has been evaluated for its anti-tumor efficacy in clinical trials by targeting IL-13RA2, but failed due to side effect. References: (1) Arima, K., et al., Characterization of the interaction between interleukin-13 and interleukin-13 receptors. J Biol Chem, 2005; 280: 24915-22.
QC	ELISA assay showing protein binding affinity of the monoclonal antibody. The calculated EC50 value was 0.05 nM.
Concentration	As indicated on the vials
Formulation	80% PBS, pH 7.4; 20% Glycerol; 5% Trehalose; 0.04% Sodium azide as Preservative
Shipping	Blue ice
Storage	-20 to -70 ^oC (long term) or 4 ^oC (one week). Depending on the expected application frequency, the product can be aliquoted to avoid heavily repeated freezing/thawing cycles.

Home \| Privacy Policy \| Terms & Conditions \| Online Price Policy \| Shipping & Return

Copyright © 2007-2023 Excellgen, Inc. All rights reserved